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Introduction
Drug-drug interactions (DDIs) are an important clinical and public health concern. Although 
DDI screening now occurs during drug development, it is difficult to predict clinical 
importance based on in vitro experiments. Further, older drugs that were not screened may 
have as-yet unidentified interactions. In this commentary, we review the importance of 
DDIs, and argue that a translational research approach is needed to produce clinically 
actionable information as well as generalizable biologic knowledge.
The clinical and public health importance of drug-drug interactions
Fifty-six percent of all adult Americans and 90% of Americans age 65+ take at least one 
prescription drug in any given month.(1) Known drug-drug interactions (DDIs) are 
responsible for 13% of adverse drug events in community-dwelling older adults (2) and 3% 
of all hospital admissions.(3) As these figures include only well-documented DDIs, they are 
undoubtedly underestimates. Given the continued development of new drugs, the rising 
frequency of polypharmacy and the aging of the population, the clinical and public health 
importance of DDIs will continue to grow. In a 2002 public opinion poll, 70% of 
respondents indicated that, if hospitalized, they would be “concerned about receiving two or 
more medicines that interact in a negative way.”(4) Over 100,000 two-drug DDIs have been 
hypothesized,(5) and many more potential DDIs may exist. However, the mechanisms and 
clinical importance very few of these have been studied thoroughly, and largely 
uninformative papers predominate in the literature. For example, approximately 70% of the 
primary literature on warfarin DDIs consists of case reports.(6) As a consequence of this 
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lack of informative data, the extent of disagreement among major DDI compendia is truly 
startling. For example, one study found that only 2.2% of the interactions listed as “major” 
in any of four major compendia were listed as such among all four; 72% were listed as 
major in only one compendium.(7) Further, current clinical decision support systems are 
plagued by a high number of DDI alerts that clinicians perceive to be unimportant. Thus, 
both physicians and pharmacists typically override about 90% of DDI alerts. Clearly, 
clinicians need to be provided with much better tools to identify, evaluate, and manage 
potential DDIs.
Translational research
With the establishment of the Clinical and Translational Science Award program by the 
National Institutes of Health, translational research has become a major focus of federally-
funded biomedical research in the US. Although a major goal of translational research is 
timely passage of therapeutic agents from basic science into clinical practice, translational 
research is not just about product development. It is also about passing hypotheses and 
knowledge across different research settings, and back and forth between research and 
clinical care (8). Unfortunately, because of structural issues in biomedical research including 
a lack of integration among disciplines (i.e., a siloed approach to science), such passage is 
often impaired, sometimes with famously catastrophic effect. For example, impaired 
translation of hypotheses and findings across animal studies, experimental human 
pharmacologic studies and pharmacoepidemiologic studies is thought to be largely 
responsible for the considerable delay in identifying the risk of myocardial infarction 
associated with rofecoxib and other cyclooxygenase-2 inhibitors. One important goal of 
translational research is to reduce such delays in the identification of clinically important 
pharmacologic effects. One area where such an approach is acutely needed is DDIs. This 
need is discussed below.
The need for translational research on drug-drug interactions
The goals of DDI research include screening for previously unanticipated DDIs; elucidating 
their potential pharmacokinetic and/or pharmacodynamic mechanisms; predicting and 
examining their effects on pharmacokinetic and clinical outcomes; and developing and 
evaluating approaches to manage their risks in clinical settings. Figure 1 depicts many of the 
research approaches used to study DDIs. These approaches include systems pharmacology 
approaches such as mining of published pharmacologic data; mining of spontaneous adverse 
drug event reports; mining of organized health care data such as electronic health records; in 
vitro studies of enzymes, microsomes or hepatocytes; in silico simulation of 
pharmacokinetic parameters; in vivo studies of pharmacokinetic parameters; population 
pharmacokinetic studies (i.e., analyzing pharmacokinetic data obtained in the course of 
clinical care); pharmacoepidemiologic studies of clinical outcomes; and development and 
evaluation of approaches to avoid DDIs or manage their risks in clinical settings. 
Importantly, each of these approaches provides a different kind of information about 
potential DDIs, and all are complementary. Thus, the biomedical research disciplines needed 
to study DDIs and their management are quite diverse, and include basic and clinical 
pharmacology, biomedical informatics, pharmacoepidemiology, design and evaluation of 
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clinical decision support tools, and others. Given the heterogeneity of these disciplines, 
translation of knowledge and hypotheses across them is challenging but crucial. Researchers 
in these disciplines have different scientific orientations and use different vocabularies. 
There is therefore a great need to translate (both figuratively and literally) among them. 
Further, research on DDIs contributes to broader pharmacologic knowledge about the drugs 
involved and the biological pathways involved in their kinetics and dynamics, thus yielding 
generalizable biologic knowledge.
Given this background, the paper by Floyd and colleagues (9) in this issue of Clinical 
Pharmacology and Therapeutics is notable in that it applies three distinct approaches to 
identify and evaluate the potential DDIs between cerivastatin and clopidogrel. These 
approaches are methodologically quite varied, consisting of 1) a screening study of 
epidemiologic and medico-legal data; 2) an analysis of spontaneously reported adverse drug 
events; and 3) in vitro experiments of enzyme inhibition. As the investigators recognize, 
their screening case-control study relied on several untestable assumptions, including that 
cerivistatin-exposed rhabdomyolysis cases who sued the manufacturer consumed the same 
concomitant medications as cerivastatin-exposed rhabdomyolysis cases who did not sue; 
that plaintiffs who participated in the study consumed the same concomitant medications as 
non-participants; that users of atorvastatin consumed the same concomitant medications as 
users of cerivastatin; and that pharmacy and medical record records of medication use in 
enrolled cerivastain-exposed rhabdomyolysis cases were equally valid and complete as the 
medication-bottle-assisted interviews of atorvastatin-taking controls without 
rhabdomyolysis. Despite reliance on such assumptions, this exercise generated useful 
hypotheses that were then examined in subsequent studies. As the investigators also 
recognized, the analysis of spontaneous reports relied on the assumption that use of 
concomitant medications did not influence reporting of rhabdomyolysis cases. We note that 
the use of spontaneous reports to follow up of signals from epidemiologic studies is the 
reverse of the usual sequence used in pharmacovigilance, and that analyses of spontaneous 
reports can rarely be considered definitive. In addition, there are methodologic pitfalls that 
must be avoided in the laboratory, and care in the extrapolation of in vitro data is essential. It 
is often the case that an I/Ki threshold is used as to predict the clinical importance of a 
potential DDI, where I is the concentration of inhibitor in the circulation, and Ki is the 
equilibrium constant of that inhibitor for a recombinant enzyme. However, concentrations of 
inhibitor in the blood are often poor predictors of concentrations at the biologic “effect site” 
at the relevant enzyme or transporter, and there is often an imperfect relationship between 
drug concentration and effect. Therefore, in vitro data should be interpreted with great 
caution. Nevertheless, this and another recent paper (10) represent early and promising 
efforts to employ a translational approach to identify and study potential DDIs, and there is 
clearly much to be learned by examining laboratory-derived hypotheses through 
pharmacoepidemiologic studies, and vice versa.
Conclusion
The science of DDIs, including their mechanisms, clinical importance, and optimal 
management will require integrated research by a wide range of investigators. Further, 
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optimal clinical management of potential DDIs will require knowing much more than 
simply whether the involved drugs can interact. Other important questions include:
• Through what mechanism(s) does the DDI occur?
• What events are caused by the DDI?
• To what degree does the DDI increase the absolute risk?
• Does the risk remain constant or change over time?
• What patient factors (e.g., age, co-morbidities, laboratory values, concomitant 
medications) affect risk?
• What management factors (e.g., empiric dosage reduction, therapeutic drug 
monitoring) affect risk?
• Are there reasonable therapeutic alternatives that would avoid this risk?
Answering these questions will require varied research designs and expertise, and will 
benefit greatly by integration of the various scientific disciplines involved. In addition to 
helping patients and clinicians, DDI research can yield generalizable biologic knowledge. 
We look forward to continued integration in the conduct of translational research on DDIs.
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Figure 1. 
Research designs for studying drug-drug interactions and their management.
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